A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
Public ClinicalTrials.gov record NCT01283139. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2b, Dose-ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To evaluate the efficacy and safety of sifalimumab compared to placebo in subjects with moderately to severely active Systemic Lupus Erythematosus (SLE).
Study identification
- NCT ID
- NCT01283139
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 834 participants
Conditions and interventions
Conditions
Interventions
- Sifalimumab 200 mg Biological
- Sifalimumab 600 mg Biological
- Sifalimumab 1,200 mg Biological
- Placebo Other
Biological · Other
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2011 (Actual)
- Primary completion
- Nov 14, 2013 (Actual)
- Completion
- Apr 17, 2014 (Actual)
- Last update posted
- Apr 19, 2018
2011 – 2014
United States locations
- U.S. sites
- 17
- U.S. states
- 11
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | La Jolla | California | — | — |
| Research Site | Palm Desert | California | — | — |
| Research Site | San Leandro | California | — | — |
| Research Site | Fort Lauderdale | Florida | — | — |
| Research Site | Orlando | Florida | — | — |
| Research Site | Stockbridge | Georgia | — | — |
| Research Site | Idaho Falls | Idaho | — | — |
| Research Site | Shreveport | Louisiana | — | — |
| Research Site | Baltimore | Maryland | — | — |
| Research Site | Lansing | Michigan | — | — |
| Research Site | Brooklyn | New York | — | — |
| Research Site | Manhasset | New York | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Charlotte | North Carolina | — | — |
| Research Site | Raleigh | North Carolina | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Seattle | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 90 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01283139, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 19, 2018 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01283139 live on ClinicalTrials.gov.